Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Healthcare solutions

Sub-section menu :

Content :

Healthcare Solutions

Cardiovascular diseases

In the UK, there are an estimated 7 million people living with cardiovascular disease; a group of disorders of the heart and blood vessels. Building on a legacy in cardiovascular, Sanofi strives to deliver therapeutic solutions that are innovative, integrated and personalised.

Dermatology

Atopic Dermatitis (AD) is a chronic inflammatory disease with symptoms appearing on the skin. In the UK, approximately 1.5 million (3%) adults have AD and the vast majority of cases are diagnosed before the fifth birthday. It can be extremely difficult for people to deal with AD; physically due to the pain and discomfort, as well as psychologically, socially and emotionally.

Diabetes

Diabetes is a chronic condition caused by either a lack of insulin in the body (type 1) or the inability of the body to use the insulin the pancreas produces (type 2). In the UK, an estimated 4.5 million people are believed to be living with the condition, around 90% of these have type 2. Sanofi has been involved in the development of insulin treatments for close to a century and has long been committed to go beyond the medicine to help improve the management of diabetes and the quality of life of people living with diabetes.

Multiple sclerosis

Over 100,000 people in the UK have Multiple Sclerosis (MS) which works out at about one in every 600 people on average, with most people with MS being diagnosed in their 20s and 30s. Sanofi Genzyme has worked for over a decade to develop new treatments for MS. We are committed to being a long-term partner to the MS community by working to deliver scientific advancements that will have a significant impact on the unmet needs of people living with MS.

Oncology

In the UK, there are now an estimated 2.5 million people living with cancer. This is expected to rise to 4 million by 2030. The number of people living with cancer in the UK in 2015 had increased by almost half a million people in five years. By working with academic research teams, biotech companies and specialised cancer centres, Sanofi plays an active role in fostering innovation in treating cancer.

Rare diseases

A rare disease is defined by the European Union as one that affects less than 5 in 10,000 of the general population and ultra-rare diseases affect 1 in 50,000 people. There are more than 7,000 rare diseases in the world and 30% of children affected will die before reaching their 5th birthday. We are committed to finding new therapeutic solutions for patients who have debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Rheumatology

Rheumatology is a word used to describe diseases related to joint pain or joint disease. One of them, rheumatoid arthritis (RA), impacts the daily life of more than 400,000 people in the UK. With the new advances in the science, the development of biologics is now paving the way to innovative approach to control severe diseases more effectively

Consumer healthcare

Self-care contributes significantly to better health and more sustainable healthcare systems and will become increasingly important in the years to come. At Sanofi, we aim to empower millions of individuals to manage their own health with effective self-care solutions and reliable information. In the UK, we focus our efforts in digestive health, pain care, allergy and vitamins and mineral supplements.

Vaccines

With the exception of clean, safe drinking water, no human endeavour rivals immunisation in combating infectious diseases and reducing mortality rates. At Sanofi, we believe in a world in which no one suffers or dies from a vaccine-preventable disease. In the UK we focus on influenza and travel vaccines but also work in paediatrics, boosters and meningitis.

 

Date of preparation: October 2017 - Job bag number: SAGB.SA.17.09.1196

Updated: October 16, 2017